Compare NTNX & ALGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTNX | ALGN |
|---|---|---|
| Founded | 2009 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Industrial Specialties |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.4B | 12.0B |
| IPO Year | 2015 | 2000 |
| Metric | NTNX | ALGN |
|---|---|---|
| Price | $39.84 | $190.02 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 11 |
| Target Price | $69.93 | ★ $189.40 |
| AVG Volume (30 Days) | ★ 4.0M | 1.1M |
| Earning Date | 02-21-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 227.45 | N/A |
| EPS | 0.21 | ★ 3.77 |
| Revenue | ★ $2,537,927,000.00 | $387,126,000.00 |
| Revenue This Year | $14.31 | $5.33 |
| Revenue Next Year | $13.96 | $4.61 |
| P/E Ratio | $196.90 | ★ $50.20 |
| Revenue Growth | 18.11 | ★ 23.95 |
| 52 Week Low | $35.39 | $122.00 |
| 52 Week High | $83.36 | $208.31 |
| Indicator | NTNX | ALGN |
|---|---|---|
| Relative Strength Index (RSI) | 40.89 | 60.96 |
| Support Level | $40.18 | $186.28 |
| Resistance Level | $41.78 | $191.48 |
| Average True Range (ATR) | 1.67 | 7.53 |
| MACD | 0.52 | 0.65 |
| Stochastic Oscillator | 71.40 | 75.24 |
Nutanix Inc is engaged in cloud software, offering organizations a single platform for running applications and managing data anywhere. Its Nutanix Cloud Platform is designed to enable organizations to build a hybrid multicloud infrastructure, providing a consistent cloud operating model with a single platform for running applications and managing data in core data centers, at the edge, and in public clouds, all while supporting a variety of hypervisors and container platforms. The company operates a single operating and reportable segment based on a subscription business model. It conducts business in the United States, Europe, the Middle East and Africa, Asia Pacific, and other Americas, with key revenue generated from the United States.
Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.